看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。+ [# l% Y v! F. ~* q
. l9 u; r t( o% v
0 x$ S! n6 v. B0 X( PCurrently available feasibility data for possible combination strategies.
' v e! j! _6 a7 Z; q% u————————————————————————————————1 t2 K7 U1 Y& ~3 H
Combination Feasibility according to preliminary data
6 [. J! N0 ?. B( s9 V5 ]—————————————————————————————————— j \, @% D. Y4 E4 v- _
Bevacizumab + sorafenib Yes, reduced dose
$ \) n! M+ J, j. g$ U: A! SBevacizumab + sunitinib† No : a& u: O% B ]" Z7 [! F
Bevacizumab + temsirolimus Yes
7 v$ T) i! m. x7 ~( T- r1 WBevacizumab + everolimus Yes ( H! o% [ ]: q# Z5 s& @7 l6 F) B
Sorafenib + sunitinib ? & T7 s( u0 A; A4 b% ^, J2 R
Sorafenib + temsirolimus Yes, reduced dose $ c( q7 w) ]1 \. A+ h/ _% z
Sorafenib + everolimus Yes, reduced dose ; G7 B9 o! H$ M0 g
Sunitinib + temsirolimus† No
* L$ W7 F6 N5 l) t+ q! e$ n7 eSunitinib + everolimus ?
% W' a- q6 f) o! p- g7 zTemsirolimus + everolimus ? & G! w8 c, u' j* [
————————————————————, r8 p& l6 J/ K8 g7 j8 x
†Led to US FDA warning.* k% m8 r* b( Y: i8 t4 {+ P
?: As yet unattempted combination.: u2 q/ c0 B8 i6 s/ W2 k M. y7 l
|